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Introduction 
Acute Myeloid Leukaemia (AML) is the most common acute leukaemia in adults with the lowest 
survival rate1 and an incidence of 602 cases per 100,000 person-years in the United Kingdom23. Despite 
recent advances in its treatment, it remains a therapeutic challenge due to its clinical and biological 
heterogeneity. AML is a clonal disorder of haemopoietic stem cells. It is characterised by the abnormal 
proliferation, differentiation and accumulation of immature myeloid cells, which reduces the 
production of healthy haemopoietic cells4. It can arise as a “de novo” malignancy in previously healthy 
individuals, secondary to other haematological disorders or following previous treatment3. Patients 
usually presents with fatigue, weight loss and signs of bone marrow failure, such as anaemia, 
thrombocytopenia and neutropenia, and a history of bruising and recurrent infections. Diagnosis 
involves the presence of more than 20% of blasts in the bone marrow and lineage is usually confirmed 
by immunophenotyping. It is an aggressive disease and left untreated can lead to death within 
months.  
Prognosis can be affected by both patient related and disease related factors. Old age and a low 
performance status are associated with a high risk profile and poor prognosis5, 6. Cytogenetic analysis 
at diagnosis is also recognised as an important prognostic factor. In current clinical practice, patients 
are routinely risk stratified according to their FMS-like tyrosine kinase 3 (FLT3) and Nucleophosmin 1 
(NMP1) mutational status to determine the most effective treatment7. Two FLT3 mutations are found 
in AML, the tyrosine kinase domain mutations (TKD, about 5-10% of patients) and in-frame, internal 
tandem duplication (ITD, about 23% of patients)8. FLT3 ITDs mutations in patients with AML are more 
prevalent with increasing age and are associated with an overall poor clinical outcome9. NPM1 
mutations are most prevalent in patients with normal karyotype and are associated with a favourable 
outcome10. Conventional treatment includes induction chemotherapy to induce complete remission 
and consolidation to eliminate any residual leukaemic cells from the bone marrow. This often involves 
bone marrow transplantation, for patients who are deemed fit enough. 
One of the biggest challenges in AML is the high relapse rate following an initial response to 
chemotherapy. New therapeutic strategies are needed, focusing on the elimination of the remnant 
chemo-resistant leukaemic cells which ‘hide’  within the protective niches of the bone marrow (BM). 
Here, they are surrounded by other cell types, including stromal cells,  that promote their survival by  
enabling them to evade destruction by both their own immune system11-15 and intra-vascular 
therapies. This ultimately leads to progression of chemotherapy resistant AML16. The mechanism of 
stromal -mediated protection of leukaemic cells, and their anchorage in the BM, is complex and 
involves many cytokines, chemokines and adhesion molecules. As shown in Figure 1, the stromal cell-
derived factor-1 (SDF-1, also known as CXCL12) and it’s receptor, CXCR4 have been implicated as 
critical mediators. Targeting this axis is an exciting therapeutic strategy and is therefore the focus of 
this review. 
 
Figure 1: Summary of the main effects of CXCL12/CXCR4 axis in the AML microenvironment 
The CXCL12/CXCR4 axis 
CXCR4 expression 
CXCL12 binds to CXCR4, a G-protein coupled chemokine receptor, which is functionally expressed in 
several cell types, including the haematopoietic stem cells (HSC). Similar to normal HSC, the majority 
of AML blast cells, predominately primitive subsets17, also express CXCR418. Interestingly, 
undifferentiated AML shows a very limited pattern of chemokine production and chemokine receptor 
expression, where only CXCR4 is expressed. AML cells with monocytic differentiation or myeloid 
maturation produce higher levels of chemokines and show a more diverse receptor repertoire which 
includes CCR1, CCR2, CCR5, CCR6, CXCR1 alongside CXCR419. Although AML cells express variable levels 
of external CXCR4 on their cell surface, high levels of internal CXCR4 is also found. In particular, Tavor 
et al showed that internal CXCR4 expression was elevated in all AML cases, including cells that do not 
express surface CXCR420. Mohle et all also concluded that AML differentiation-related expression of 
CXCR4 results in preferential activity of CXCL12 in myelomonocytic blasts21. Interestingly, Sison et al 
showed that treatment of AML cell lines (MOLM-14 and MV4-11) with chemotherapy resulted in 
surface CXCR4 upregulation22. This indicates that chemotherapy can dynamically affect CXCR4 
expression in order to contribute to stromal protection of leukaemic cells from further chemotherapy-
induced apoptosis, thus contributing to leukaemic cell chemoresistance. In the same study, treatment 
with a CXCR4 inhibitor preferentially decreased stromal protection from higher chemotherapy-
induced upregulation of surface CXCR4.  
CXCL12 expression 
CXCL12 is secreted by several hematopoietic cells, including the more mature CD34+CD38+ progenitor 
cells23. In vitro experiments have shown that CXCL12 can be detected intracellularly (cytoplasm), on 
the cell membrane, and in the culture supernatant24. Tavor et al investigated the CXCL12 expression 
on AML cells and confirmed that it is expressed both intracellularly as well as on the cell surface. These 
results suggest that the malignant cells also secrete this chemokine20. However, primary human AML 
cells have been shown to release detectable CXCL12 in only 10 out of 68 of patients18 so autocrine 
CXCL12 /CXCR4 loops are not common in AML. The major sources of CXCL12 in AML BM are stromal 
cells and CXCL12-abundant reticular (CAR) cells, which are progenitors of mesenchymal stem cells 
surrounding the sinusoids or located near the endosteum25. Endothelial cells and osteoblasts also 
secrete lower levels26. Mice lacking CXCL12 have reduced myeloid progenitors in the bone marrow but 
not in the foetal liver, indicating that this chemokine is mainly responsible for bone marrow retention 
and myelopoiesis27.  
Survival and proliferation 
Suzuki et al investigated the effect of CXCL12 on CD4+ T cells and showed that cell survival was 
promoted through this pathway by two main mechanisms: increased transcription of survival genes 
and posttranslational inactivation of apoptotic genes28. The CXCL12 /CXCR4 interaction 
phosphorylates CXCR4, which then promotes calcium flux and activates signalling pathways, including 
MEK/ERK, JAK/STAT, and PI3K/AKT axes, thus promoting cell survival29. CXCL12 promotes the survival 
of AML cells and the addition of blocking CXCL12 antibodies or CXCR4 inhibitors significantly decreases 
it20. Schelker et al showed that in vitro co-culturing of AML cells on BM-derived human mesenchymal 
stem cells resulted in greater proliferation, which was significantly reduced when CXCR4 was 
blocked30. Sugiyama et al developed an in vivo model using CXCR4 deficient mice and demonstrated 
that the absence of CXCR4 reduced the HSC pool in the adult bone marrow25. Furthermore, in another 
study the use of Plerixafor, a known CXCR4 antagonist, resulted in decreased proliferation of FLT3-ITD 
positive blast cells31.  
Migration 
The CXCL12 /CXCR4 axis is fundamental for haematopoietic stem cell migration. CXCL12 was the first 
chemoattractant described for human CD34+ progenitor cells, in which a transient elevation of 
cytoplasmic calcium was seen with a subsequent chemotactic response32. Mohle et al. used 
conditioned medium from a stromal cell line to show that CD34+ progenitor cells migrate across 
endothelium in response to CXCL12. They also used recombinant CXCL12 to confirm efficient 
migration of CXCR4+ leukaemic blasts and a CXCR4 antagonist to effectively inhibit the migratory effect 
of both17. Kalinkovich et al investigated the relationship between the CXCL12/CXCR4  axis and 
microparticles, which are vesicles shed from the plasma membrane of cells33. AML patients had 
elevated CXCR4+ microparticles and total CXCL12 levels in their peripheral blood and bone marrow 
when compared to healthy volunteers. Interestingly, the majority of CXCR4+ microparticles were 
CD45+ in AML patients and CD41+ in normal individuals. The microparticles enhanced the migration of 
the AML cell line HL-60 to CXCL12 in vitro and increased their homing to the bone marrow of irradiated 
mice; effects reduced by a CXCR4 inhibitor. Burger et al showed that CXCR4 activation and Very Late 
Antigen-4  (VLA-4) binding are fundamental for AML cell migration beneath stromal cells, a 
phenomenon called pseudoemperipolesis34. Some studies have investigated the phenotype of the 
migrated cells and showed that CXCL12 preferentially induces transmigration of primitive 
CD34+CD38−CXCR4+ cells35. Interestingly, Voermans et al showed that primary AML cells migrate 
towards CXCL12, independently of AML subtype36. Preferential or diminished migration was observed 
by leukaemic cells expressing CD34/CD38/HLA-DR and CD14/CD36 respectively. Finally, AML CD34+ 
cells derived from the bone marrow showed significantly higher CXCL12-induced migration compared 
to CD34+ cells derived from peripheral blood. Liesveld et al used the CXCR4 inhibitor AMD3100 to 
confirm inhibition of trans-endothelial transmigration by AML blasts37.  
Adhesion 
AML and normal HSC cells adhere to the BM through three main receptors: CXCR4, VLA-4 and CD4438. 
The adhesion of HSC to the BM niche via the CXCL12 /CXCR4 axis is a cooperative process, and is 
stronger than that by N-cadherin binding, which is also important in cell adhesion39. In addition to the 
effect on survival and migration of HSC and AML blasts, it has been shown that CXCL12 can enhance 
the activity of integrins thus improving adhesion and retention of CD34+ cells in the BM. During stem 
cell transplantation, CXCL12 was shown to mediate the homing of human progenitor cells to the BM. 
The CXCL12 /CXCR4–mediated bone marrow cell anchorage is crucial and it’s disruption leads to the 
release of hematopoietic cells into the circulation, a process regulated by various proteolytic 
enzymes40. Liesveld et al used a static functional co-culture assay, where he cultured stromal or 
endothelial cells with AML blasts. This study found that the addition of a CXCR4 inhibitor in the co-
culture system, did not affect the adhesion of AML cells on the endothelial monolayers. However, 
treatment with the same inhibitor decreased the expression of other receptors known to be involved 
in cell adhesion on endothelial cells37. Wagner et al demonstrated that primitive human progenitor 
haematopoietic cell subsets have higher affinity for human mesenchymal stem cells and adherent 
CD34+ cells express higher levels of genes coding for adhesion proteins and extracellular matrix 
including fibronectin, cadherin, and vascular cell adhesion molecule-1 (VCAM-1)41. Finally, CXCL12 
signalling has been shown to induce VLA-4 and Lymphocyte function-associated antigen 1 (LFA-1) on 
human cord blood cells42 which in turn induces CD34+ cell adhesion to structures that carry VCAM-1 
and intracellular adhesion molecule-1 (ICAM-1)43. 
VLA-4 expression has been associated with chemoresistance in AML. It is an integrin that can bind to 
VCAM-1, which is expressed by endothelial and stromal cells as well as fibronectin. In contrast to 
endothelial cells, only low levels of ICAM-1 or VCAM-1 are expressed on stromal cells35. In vitro studies 
have confirmed that VCAM-1/VLA-4 pathway is critical for the NF-kB activation in stromal cells and 
leukaemia cells interaction, which can promote chemoresistance44. Matsunaga et al investigated the 
interactions between VLA-4 on leukaemic cells and fibronectin on stromal cells. This interaction was 
found to be crucial in mediating adhesion of AML cells on stromal cells and in the presence of 
fibronectin, VLA-4 positive AML cells were resistant to cytotoxic drugs through the PI-3K/AKT/Bcl-2 
signalling pathway45. In the same study, the combination of blocking VLA-4 and administering cytosine 
arabinoside (AraC) achieved 100% survival in a mouse model compared to a very low survival in mice 
treated with AraC alone45. Petty et al investigated the cross talk between CXCL12/CXCR4 and VCAM-
1/VLA-4 pathways in neutrophil retention in the BM. They showed that CXCL12 signalling increases 
VLA-4 adhesion in vitro. Blocking both receptors caused a synergistic effect, releasing neutrophils from 
the BM in vivo46.  
Hyaluronic acid (HA) is the main ligand for the adhesion receptor CD44 and their interaction is 
essential for CD34+ stem/progenitor cell homing into the BM, a process blocked when anti-CD44 
antibody is used. Jin et al used an in vivo model to show that the administration of a monoclonal 
antibody against CD44 resulted in significant reduction in leukaemic repopulation by interfering with 
the leukaemic stem cell- BM microenvironment47. Interestingly, CXCL12 was shown to stimulate 
progenitor cell adhesion to immobilised HA, which was found to be highly expressed on the 
endosteum and sinusoidal endothelium where CXCL12 is also abundant. These findings are evidence 
in support of a potentially significant crosstalk between the two pathways in HSC trans-endothelial 
migration and anchorage to the BM niche48.  
E-selectin is another important adhesion molecule that plays a fundamental role in AML cell migration 
and homing. Using an in vitro assay, it was shown to contribute to the adhesion of AML blasts on 
human endothelium49. Chien et al used a human AML in vivo model to show that an E-selectin inhibitor 
successfully mobilised AML blasts by blocking their adhesion50. In another study, Noguchi et al showed 
that a minor E-selectin ligand, CD65, was an independent risk factor for  extravascular infiltration of 
AML51. 
Adaptation to hypoxic environment 
CXCR4 has also been shown to have a central role in cell adaption to the hypoxic environment. One of 
the key features of the HSC in the BM microenvironment is their hypoxic profile. They have been 
shown to exhibit increased pimonidazole (Pimo)52, a known marker of hypoxia, and express Hypoxia-
inducible transcription factor 1 alpha (HIF-1α)53. HIF-1α has been detected in many cell culture systems 
under 5% oxygen (40mmHg) and usually gets degraded by proteasomes under normoxic conditions 
(21% oxygen)54. Interestingly Ceradini et al showed that HIF-1α regulates  CXCL12 gene expression in 
endothelial cells, which increases the migration and adhesion of CXCR4 positive circulatory cells to 
ischaemic tissue55. Using osteosarcoma cells, Guan et al confirmed that hypoxia promotes the 
expression of HIF-1a and that CXCR4 expression can be upregulated by HIF-1a in hypoxia, a phenotype 
which persists after the cells are transferred to normoxic conditions56. CXCR4 is known to play an 
important role in the pathology of Chronic Lymphocytic Leukaemia (CLL)57 and HIF-1a  mRNA 
expression was shown to correlate with that of CXCR4 in CLL patients. In further support, Valsecchi  et 
al demonstrated that co-culturing CLL cells with HS5 stromal cells induces an increase in HIF-1a mRNA 
which also increases the expression of HIF-1a target genes including CXCR458.  
Prognosis 
The prognostic impact of the CXCL12/CXCR4 axis in leukaemia has been studied in detail. High and 
intermediate CXCR4 expression on AML cells is associated with decreased overall and relapse-free 
survival59. Raised CXCR4 expression on CD34+ cells in particular is associated with even poorer 
prognosis and a higher relapse rate. In a study by Rombouts et al it was shown to be significantly 
higher in FLT3-ITD AML, one of the most frequent mutations in AML, conferring poor response to 
chemotherapy60. However, in another study, CXCR4 expression was shown to be associated with poor 
prognosis in AML patients irrespective of FLT3 gene mutation status61.  
CXCR4 inhibitors 
Several CXCR4 inhibitors have been developed and used in pre-clinical and clinical models for 
mobilisation of haemopoietic cells. They can be small molecules (e.g. AMD3100), peptides (e.g. BL-
8040), or monoclonal antibodies (e.g. Ulocuplumab)62.  A few of the most important inhibitors that 
have been tested throughout the years are described below. 
Plerixafor (AMD3100) 
Plerixafor, previously known as AMD3100, is a CXCR4 receptor antagonist, which was developed to 
block HIV but found to cause leukocytosis in a phase 1 study in normal volunteers63. This finding led 
to further development of the drug, and it was shown to increase circulating CD34+cells in healthy 
volunteers and cancer patients when administered alone or in combination with granulocyte colony 
stimulating factor (G-CSF). G-CSF is known to decrease CXCL12 and upregulate CXCR4, thus also 
induces stem cell mobilisation64, 65. Liles et al reported administration of Plerixafor in 26 healthy 
volunteers resulted in leukocytosis with only mild, transient toxicity66. Plerixafor is now approved for 
the mobilisation of autologous hematopoietic stem and progenitor cells in patients with multiple 
myeloma and non-Hodgkin lymphoma67.  
To investigate the effect of blocking and reducing the CXCL12/CXCR4 axis on AML cells, Shen at al 
devised a biomimetic polystyrene scaffold model propagated with osteoblasts, stromal cells and AML 
cells. Their results confirmed that combining G-CSF and Plerixafor blocked the protective effect of the 
other cells on the AML and enabled greater levels of chemotherapy induced apoptosis 68.  Nervi et al 
used a murine acute promyelocytic leukaemia (APL) model and Plerixafor to examine the interaction 
of the leukaemia cells with the BM niche. Administration of Plerixafor to mice mobilised leukaemic 
cells into the peripheral circulation and the spleen, inducing a 1.6-fold increase in total leukocytes and 
a 9-fold increase in circulating blasts. Plerixafor treatment of the leukaemic mice significantly 
enhanced chemotherapy efficacy. They also showed that co-culturing of the murine APL cells with M2-
10B4 stromal cell line protected them against chemotherapy-induced apoptosis, mainly through 
soluble factors released from stromal cells (non-contact dependent)69. Zhang et al provided insight 
into the mechanism of action of Plerixafor and another small peptide CXCR4 inhibitor, ALX40-4C. Both 
drugs were shown to induce CXCL12-like G-protein activation in CXCR4-expressing cells70. A number 
of early phase clinical trials involving Plerixafor in AML have been initiated, investigating its effect in 
combination with chemotherapy. The most important are summarized below: 
 
Author 
Uy GL71 Deol A64 Cooper TM72 Martínez-Cuadrón D74 Roboz et al75 Michelis et al73 
Year 2012 2013 2017 2018 2018 2019 
Aim Assess toxicities, 
remission rate and 
blast mobilisation  







Establish a safe and 
efficient dose 
Investigate the 





Patients 52 patients with 
relapsed/ refractory 
AML 
49 patients who 
failed at least 1 
mobilisation attempt 
19 patients (13 
AML, 5 ALL, 1 MDS) 
41 patients with AML 69  patients with 
newly diagnosed 
AML 
12 patients with 
AML 














Results Dose escalated 
without toxicities.  
Overall complete 
remission rate was 
46%. There was a 2-
fold mobilisation in 
leukaemic blasts 
into the peripheral 
circulation. 
2.5 × 106 CD34+ 
cells/kg were 
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Plerixafor mobilised 









7% died during 
induction. Median 
overall and disease-
free survivals were 9.9 
and 13 months, 
respectively 
Overall response 











and 50% were 
alive at the last 
follow-up. The 
median follow-up 
of survivors was 
67 months.  

















etoposide, was well 
tolerated 
The combination 
treatment resulted in a 
relatively high 
complete remission 
with an acceptable 
toxicity profile 
Plerixafor can be 
safely added to 
decitabine in poor-
prognosis, elderly 
AML patients  
Plerixafor 
administration is 
safe and well 
tolerated. Further 




AMD3465 is a selective small molecule CXCR4 antagonist that was initially shown to have a therapeutic 
potential by mobilizing leucocytes in mice and dogs76. It has been described as more potent than 
Plerixafor and inhibits surface CXCR4 expression on AML cell membrane in a dose dependent 
manner77. Zeng et al showed that AMD3465 induced cell mobilisation in AML cell lines and enhanced 
the chemotherapy induced apoptosis of primary AML blasts in stromal co-culture systems. AMD3465 
in combination with chemotherapy resulted in complete leukaemia eradication using an in vivo model. 
FLT3 mutated AML have been shown to be resistant to both chemotherapy and FLT3 inhibition, and it 
has been suggested that this is due to the pro-survival pathways (PI3K/Akt and MEK/ERK), which are 
activated by the stroma67. Using transfected murine cell lines, Zeng et al showed that AMD3465 
enhanced the apoptotic effects of an FLT3 inhibitor on FLT3-mutated cells, an effect which was greater 
in hypoxic conditions. Finally, AMD3465 was shown to mobilise FLT3 mutated leukaemic cells (7.5 fold 
increase in peripheral blood) and enhance apoptosis in vivo29. 
BL-8040 (formerly known as BTK140) 
BL-8040 (BKT140) is a new generation peptide CXCR4 inhibitor with higher affinity than Plerixafor and 
causes significant and preferential apoptosis in leukaemia cells78. In addition, it has been shown to 
induce disease regression in primary AML xenograft models79. BL-8040 has been used in combination 
with chemotherapy in a safety and efficacy clinical trial and  given to patients with relapsed/refractory 
AML. The study showed promising initial results, demonstrating that it has potent anti-leukaemic 
activity, can mobilise leukaemic blasts from the BM to the periphery and may improve the clinical 
response in combination with chemotherapy80. More recent clinical trials demonstrated that BL-8040 
induced rapid mobilisation of human CD34+ cells and can be a safe and effective monotherapy prior 
to transplantation81. The combination of BL-8040 and cytarabine in relapsed/refractory AML improves 
response rate and when used as a single agent BL-8040 can induce mobilisation, differentiation and 
apoptosis of AML blasts82. Abraham et al investigated the effect of BL-8040 on AML cell survival and 
mobilisation. They showed that BL-8040 induced AML cell apoptosis both in vitro and in vivo via 
upregulation of miR-15a/miR-16-1, which subsequently caused downregulation of anti-apoptotic 
genes including BCL-2, MCL-1 and cyclin-D1. Survival signals via the AKT/ERK pathways were also 
inhibited, which contributed to the apoptotic effect. Finally, Abraham et al shoed that co-targeting 
CXCR4 with BCL-2 or FLT3 inhibitors enhanced the apoptotic effect, which provides a rationale for 
further research in combination therapies to achieve synergistic effects83. 
LY2510924 
Cho et al reported that another potent peptide CXCR4 inhibitor, LY2510924, inhibited CXCL12-
induced chemotaxis and pro-survival signals of AML cells more effectively than Plerixafor. In vitro, 
LY2510924 inhibited AML cell proliferation and reduced stromal induced protection against 
chemotherapy. In vivo, LY2510924 induced mobilisation of leukaemic cells into the circulation. They 
concluded that LY2510924 effectively disrupts CXCL12/CXCR4, thus providing an effective anti-
leukaemia agent both as a monotherapy as well as in combination with chemotherapy84.  
TN140 
TN140 is a small peptide inhibitor that is not yet approved for clinical use. The in vivo effects of TN140 
were investigated using a murine model of AML. TN140 was shown to functionally block CXCR4 and 
lead to a reduction in leukaemic cells in the BM following their mobilisation to the blood. After 
treatment, the leukaemic cells recovered from the BM had a marked decrease in ERK phosphorylation 
which suggests that TN140 affects survival signalling pathways. Most importantly, TN140 reduced 
relapse after secondary transplantation and treated mice had a prolonged survival. Using an in vitro 
assay the authors confirmed that treatment with TN140 inhibits the migration response of CXCL12 
and disrupts the adhesion of AML cells on stroma79.  
Ulocuplumab (BMD-936564/MDX-1338) 
Kuhne et al. investigated the effect of potent fully human IgG4 monoclonal antibody, Ulocuplumab, 
that recognises human CXCR4 in AML, non–Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia 
(CLL) and multiple myeloma and has a longer half-life than Plerixafor. In vitro models showed that 
Ulocuplumab inhibits calcium flux and CXCL12-induced migration. It also has antitumor activity  when 
given as a monotherapy85. The first in man phase I clinical trial assessing the clinical benefit of 
Ulocuplumab in relapsed/refractory AML resulted in improved response rate when used in 
combination with mitoxantrone, etoposide and cytarabine (MEC). The overall complete remission (CR) 
and complete remission with incomplete blood count (CRi) recovery rate was 51% versus 24-28%, 
which has been historically achieved using MEC alone86. 
Conclusion 
AML is the most common adult acute leukaemia with the lowest survival rate.  It remains a therapeutic 
challenge due to its heterogeneity and high relapse rate. The CXCL12/CXCR4 axis is central to its 
pathogenesis and affects leukaemic blast migration, survival and adhesion to the protective BM niche. 
Here it is sheltered from the toxic effects of chemotherapy.  Blocking the CXCL12/CXCR4 axis is an 
attractive therapeutic strategy and several new CXCR4 inhibitors have been developed with promising 
initial results.  Further investigation into the development of a ‘multi-hit’ therapy that targets several 
signalling pathways related to AML cell adhesion and maintenance in the BM is essential.  The 
successful release of the AML cells from the BM into the circulation would enable them to be targeted 
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